EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Milestone Pharmaceuticals's enterprise value is $74.53 Mil.
Milestone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-57.63 Mil. Therefore, Milestone Pharmaceuticals's EV-to-EBITDA for today is -1.29.
The historical rank and industry rank for Milestone Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
MIST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.31 Med: -2.04 Max: -0.8
Current: -1.29
During the past 7 years, the highest EV-to-EBITDA of Milestone Pharmaceuticals was -0.80. The lowest was -6.31. And the median was -2.04.
MIST's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs MIST: -1.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Milestone Pharmaceuticals's stock price is $1.66.
Milestone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.390. Therefore, Milestone Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Milestone Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Milestone Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Milestone Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Milestone Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's EV-to-EBITDA falls into.
Milestone Pharmaceuticals's current Enterprise Value is $74.53 Mil.
Milestone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Milestone Pharmaceuticals's PE Ratio for today is calculated as:
Milestone Pharmaceuticals's share price for today is $1.66.
Milestone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Milestone Pharmaceuticals EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Milestone Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MIST has been successfully added to your 